Intravitreal Triamcinolone Acetonide Injection for the Treatment of Posterior Uveitis
- 1 January 2006
- journal article
- Published by Informa UK Limited in Ocular Immunology and Inflammation
- Vol. 14 (4), 233-238
- https://doi.org/10.1080/09273940600826604
Abstract
To assess the efficacy and complications of intravitreal triamcinolone acetonide (IVTA) injection in the treatment of posterior uveitis and to compare the outcomes with patients who had received systemic corticosteroids. This prospective, interventional, clinical case series study included 11 eyes of 9 patients who received 8 mg/0.2 ml of IVTA injection for posterior uveitis that involved vitreous inflammation (group 1). Control group (group 2) consisted of 15 eyes of 12 patients who had received systemic corticosteroids for treatment of posterior uveitis with vitreous inflammation. The main outcome measures included best-corrected visual acuity, vitreous inflammation score and intraocular pressure. In group 1, mean visual acuity improved significantly (P < 0.001) from a mean logarithm of the minimum angle of resolution (LogMAR) value of 2.05 +/- 0.82 at baseline to a maximum of 0.33 +/- 0.22 during the follow-up period of 5.0 +/- 2.8 months. In control group, mean LogMAR visual acuity before systemic corticosteroid therapy was 1.82 +/- 0.78, and it has reached a maximum of 0.40 +/- 0.22 after treatment (P < 0.001). The mean inflammatory scores decreased significantly in both groups when compared with preinjection values (for each, P < 0.05). There were no statistically significant differences between group 1 and group 2 when pre-and posttreatment visual acuities and inflammatory scores at 1-, 3-, and 5-month follow-up examinations were compared (for each, P > 0.05). In group 1, mean intraocular pressure (IOP) increased significantly from 13.4 +/- 2.6 mmHg to a mean maximal value of 19.3 +/- 4.3 mmHg (P < 0.001), but there was no statistically significant difference between mean IOP at 5-month after IVTA injection and pretreatment value (P = 0.06). Cataract progression was observed in one eye. IVTA application may be an alternative therapeutic option for the treatment of acute posterior uveitis that involves vitreous inflammation, especially in patients who carry risks for systemic corticosteroid therapy.Keywords
This publication has 24 references indexed in Scilit:
- Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusionEye, 2005
- The Efficacy of Intravitreal Triamcinolone Acetonide on Macular Edema in Branch Retinal Vein OcclusionEuropean Journal of Ophthalmology, 2005
- Intravitreal Triamcinolone Acetonide Injection as Primary Treatment for Diabetic Macular EdemaEuropean Journal of Ophthalmology, 2004
- Pattern electroretinogram for monitoring the efficacy of intravitreal triamcinolone injection in diabetic macular edemaDocumenta Ophthalmologica, 2004
- Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edemaAmerican Journal of Ophthalmology, 2003
- Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contributions/clinical and laboratory investigationsMediators of Inflammation, 2003
- Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injectionAmerican Journal of Ophthalmology, 2002
- Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panelAmerican Journal of Ophthalmology, 2000
- Posterior sub-Tenon's triamcinolone injections in the treatment of uveitisEye, 1998
- Causes and frequency of blindness in patients with intraocular inflammatory disease.British Journal of Ophthalmology, 1996